Monograph
S01AE03 - Ciprofloxacin |
Propably not porphyrinogenic |
PNP |
Rationale
Conflicting references regarding porphyrinogenicity, but the systemic load probably is insignificant, being about 1/500 of the peroral dose of 250 mg.
Chemical description
Quinolone chemotherapeutic in eye drops 3mg/mL, used in treatment of corneal vulnera and conjunctivitis (2 drops every 15 minutes during the first 6 hours, after that 2 drops every 30 minutes the rest of the day, etc. Continued for two weeks.) Absorbed, but the plasma concentration is low, varying between 0 and 4,7 µg/mL. South African list: use with extreme caution only French list: authorized
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom
Ciloxan · Ciloxan 0.3% eye drops · Ciloxan 3mg/g eye ointment · Ciprofloxacin · Ciprofloxacin 0.2% eye drops preservative free · Ciprofloxacin 3mg/g eye ointmentDenmark
CiloxanNorway
Cilox · CiloxanPoland
Cipronex 0,3%Luxembourg
CILOXANLatvia
CiloxanSerbia
Marocen · Marocen®
© NAPOS 2024